Edition:
United States

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

10.78USD
21 Sep 2018
Change (% chg)

$-0.17 (-1.55%)
Prev Close
$10.95
Open
$10.82
Day's High
$10.94
Day's Low
$10.29
Volume
737,266
Avg. Vol
116,518
52-wk High
$11.35
52-wk Low
$3.25

Latest Key Developments (Source: Significant Developments)

Zafgen Reports Q4 Loss Per Share $0.48
Tuesday, 6 Mar 2018 04:05pm EST 

March 6 (Reuters) - Zafgen Inc ::ZAFGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; ANNOUNCES POSITIVE INTERIM DATA FROM ONGOING ZGN-1061 PHASE 2 PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH TYPE 2 DIABETES.Q4 LOSS PER SHARE $0.48.  Full Article

Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln
Friday, 5 Jan 2018 05:04pm EST 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN SAYS ‍ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT​ OF $20 MILLION - SEC FILING.  Full Article

Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018
Friday, 5 Jan 2018 07:00am EST 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018.ZAFGEN- INCREASED CASH POSITION DURING Q4, EXPECTS TO END CALENDAR YEAR 2017 WITH OVER $100 MILLION IN CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES.ZAFGEN INC - WELL-CAPITALIZED TO SUPPORT ITS CLINICAL-STAGE DEVELOPMENT PROGRAMS BEYOND FIRST HALF OF 2019.ZAFGEN - ‍ENTERED A $20 MILLION VENTURE DEBT FINANCING AGREEMENT WITH SILICON VALLEY BANK ON DEC 29, EXTENDING EXPECTED CASH RUNWAY BEYOND H1 2019​.ZAFGEN INC - TOPLINE DATA ARE EXPECTED IN MID-YEAR 2018 FOR ZGN-1258.ZAFGEN -FOR ZGN-1258,‍ BEGINNING IND APPLICATION-ENABLING WORK IN Q1 FOR FILING WITH U.S. FDA, BEGINNING PHASE 1 CLINICAL DEVELOPMENT BY END OF YEAR​.  Full Article

Zafgen reports Q3 loss per share $0.46
Tuesday, 7 Nov 2017 04:30pm EST 

Nov 7 (Reuters) - Zafgen Inc :Zafgen reports third quarter 2017 financial results.Q3 loss per share $0.46.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Zafgen- continues to expect its cash, cash equivalents and marketable securities balance to be greater than $70 million as of december 31, 2017​.Zafgen Inc - ‍initiated phase 2 clinical trial for second generation metap2 inhibitor ZGN-1061​.  Full Article

Zafgen appoints Jeffrey Hatfield as CEO
Tuesday, 10 Oct 2017 07:00am EDT 

Oct 10 (Reuters) - Zafgen Inc ::Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer.Zafgen Inc - Hatfield and Hughes will serve on Zafgen's board of directors​.  Full Article

Zafgen initiates Phase 2 clinical trial for ZGN-1061
Tuesday, 12 Sep 2017 04:05pm EDT 

Sept 12 (Reuters) - Zafgen Inc :Zafgen initiates Phase 2 clinical trial for ZGN-1061 in patients with Type 2 diabetes.  Full Article

Zafgen Inc files for a potential mixed shelf offering of up to $150 mln
Wednesday, 9 Aug 2017 04:49pm EDT 

Aug 9 (Reuters) - Zafgen Inc :Zafgen Inc files for a potential mixed shelf offering of up to $150 million - SEC filing.  Full Article

Zafgen Q2 loss per share $0.49
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Zafgen Inc :Zafgen reports second quarter 2017 financial results.Q2 loss per share $0.49.Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

Zafgen reports Q1 loss per share $0.48
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Zafgen Inc :Zafgen reports first quarter 2017 financial results.Q1 loss per share $0.48.Q1 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.Zafgen Inc says expects that its cash, cash equivalents and marketable securities balance will be greater than $65 million as of December 31, 2017.  Full Article

Zafgen reports Q4 loss per share of $0.38
Thursday, 9 Mar 2017 04:05pm EST 

Zafgen Inc : Zafgen reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.38 . Q4 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S .Expects Co's cash, cash equivalents and marketable securities balance will be greater than $65 million as of December 31, 2017.  Full Article

BRIEF-Zafgen Reports Q1 Loss Per Share $0.58

* ZAFGEN REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS